Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCX vs TAC in High-Risk HER2-Negative Breast Cancer
NCT01354522Phase 3Completed
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2011
- Primary completion
- Dec 2023
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine in breast cancer, sponsored by Peking Union Medical College Hospital. Started May 2011; status: completed.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01354522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01354522.